These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
☒
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
Delaware
(
State or Other Jurisdiction of Incorporation or Organization)
|
11-3027591
(IRS Employer Identification No.) |
|
445 Park Avenue, Suite 912
New York, New York
(Address of Principal Executive Offices)
|
10022
(Zip Code)
|
|
Title of each class
Common Stock, par value $0.01 per share
|
Trading symbol
NTIP
|
Name of each exchange on which registered
NYSE American
|
|
Large accelerated filer ☐
|
|
Accelerated filer ☐
|
|
|
|
|
|
Non-accelerated filer ☐
|
|
Smaller reporting company ☒
|
|
Emerging growth Company ☐
|
|
Page No.
|
|
|
PART I. Financial Information
|
|
|
Item 1. Condensed Consolidated Financial Statements (unaudited)
|
|
|
Condensed Consolidated Balance Sheets as of March 31, 2019 and December 31, 2018
|
3 |
|
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the three months ended March 31, 2019 and 2018
|
4 |
|
Condensed Consolidated Statements of Stockholders' Equity for the three months ended March 31, 2019 and 2018
|
5 |
|
|
|
|
Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2019 and 2018
|
6 |
|
Notes to Unaudited Condensed Consolidated Financial Statements
|
7 |
|
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
|
30 |
|
Item 3. Quantitative and Qualitative Disclosures About Market Risk
|
36 |
|
Item 4. Controls and Procedures
|
36 |
|
PART II. Other Information
|
|
|
Item 1. Legal Proceedings
|
37 |
|
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
|
39 |
|
Item 3. Defaults Upon Senior Securities
|
40 |
|
Item 5. Other Information
|
40 |
|
Item 6. Exhibits
|
40 |
|
Signatures
|
41 |
|
March 31,
2019
|
December 31,
2018
|
|||||||
|
ASSETS:
|
||||||||
|
CURRENT ASSETS:
|
||||||||
|
Cash and cash equivalents
|
$
|
21,650,000
|
$
|
23,763,000
|
||||
|
Marketable securities, at fair value
|
30,837,000
|
31,228,000
|
||||||
|
Royalty receivables, net
|
774,000
|
444,000
|
||||||
|
Other current assets
|
83,000
|
112,000
|
||||||
|
Total Current Assets
|
53,344,000
|
55,547,000
|
||||||
|
OTHER ASSETS:
|
||||||||
|
Deferred tax assets
|
233,000
|
168,000
|
||||||
|
Patents, net of accumulated amortization
|
1,959,000
|
1,989,000
|
||||||
|
Equity investment
|
2,445,000
|
2,541,000
|
||||||
|
Operating leases right-of-use asset
|
95,000
|
—
|
||||||
|
Security deposits
|
21,000
|
21,000
|
||||||
|
|
||||||||
|
Total Other Assets
|
4,753,000
|
4,719,000
|
||||||
|
TOTAL ASSETS
|
$
|
58,097,000
|
$
|
60,266,000
|
||||
|
LIABILITIES AND STOCKHOLDERS' EQUITY:
|
||||||||
|
CURRENT LIABILITIES:
|
||||||||
|
Accounts payable
|
$
|
395,000
|
$
|
67,000
|
||||
|
Income taxes payable
|
197,000
|
197,000
|
||||||
|
Accrued contingency fees and related costs
|
198,000
|
1,136,000
|
||||||
|
Accrued payroll
|
68,000
|
486,000
|
||||||
|
Operating lease obligations – current
|
88,000
|
—
|
||||||
|
Other accrued expenses
|
140,000
|
175,000
|
||||||
|
TOTAL CURRENT LIABILITIES
|
$ |
1,086,000
|
$
|
2,061,000
|
||||
|
Operating lease obligations
|
8,000
|
—
|
||||||
|
TOTAL LIABILITIES
|
$
|
1,094,000
|
$
|
2,061,000
|
||||
|
COMMITMENTS AND CONTINGENCIES
|
||||||||
|
STOCKHOLDERS' EQUITY
|
||||||||
|
Preferred stock, $0.01 par value, authorized 10,000,000 shares;
|
||||||||
|
none issued and outstanding at March 31, 2019 and
|
||||||||
|
December 31, 2018
|
—
|
—
|
||||||
|
Common stock, $0.01 par value; authorized 50,000,000 shares;
|
||||||||
|
23,782,761 and 23,735,927 shares issued and outstanding at
|
||||||||
|
March 31, 2019 and December 31, 2018, respectively
|
238,000
|
237,000
|
||||||
|
Additional paid-in capital
|
65,294,000
|
65,151,000
|
||||||
|
Accumulated deficit
|
(8,558,000
|
)
|
(7,102,000
|
)
|
||||
|
Accumulated other comprehensive income (loss)
|
29,000
|
(81,000
|
)
|
|||||
|
TOTAL STOCKHOLDERS' EQUITY
|
57,003,000
|
58,205,000
|
||||||
|
|
||||||||
|
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
|
$
|
58,097,000
|
$
|
60,266,000
|
||||
|
Three Months Ended
March 31
|
||||||||
|
2019
|
2018
|
|||||||
|
REVENUE
|
$
|
606,000
|
$
|
19,463,000
|
||||
|
OPERATING EXPENSES:
|
||||||||
|
Costs of revenue
|
146,000 | 7,259,000 | ||||||
|
Professional fees and related costs
|
307,000 | 518,000 | ||||||
|
General and administrative
|
488,000 | 507,000 | ||||||
|
Amortization of patents
|
54,000 | 70,000 | ||||||
|
Stock-based compensation
|
144,000 | 226,000 | ||||||
|
|
||||||||
|
TOTAL OPERATING EXPENSES
|
1,139,000
|
8,580,000
|
||||||
|
OPERATING INCOME(LOSS)
|
(533,000
|
)
|
10,883,000
|
|||||
|
OTHER INCOME:
|
||||||||
|
Interest income, net
|
301,000
|
143,000
|
||||||
|
Net realized and unrealized gain from investments
|
23,000
|
—
|
||||||
|
Total other income
|
324,000
|
143,000
|
||||||
|
INCOME (LOSS) BEFORE INCOME TAXES AND EQUITY IN
|
||||||||
|
NET LOSSES OF EQUITY METHOD INVESTEE
|
(209,000
|
)
|
11,026,000
|
|||||
|
INCOME TAXES (BENEFIT):
|
||||||||
|
Current
|
—
|
|
2,425,000
|
|||||
|
Deferred taxes, net
|
(65,000
|
) |
—
|
|||||
|
Total income taxes (benefit)
|
(65,000
|
)
|
2,425,000
|
|||||
|
INCOME (LOSS) BEFORE EQUITY IN NET LOSS OF EQUITY METHOD INVESTEE:
|
(144,000 | ) |
8,601,000
|
|||||
|
Share of net losses of equity method investee
|
(96,000 | ) |
—
|
|||||
|
NET INCOME (LOSS)
|
$
|
(240,000
|
)
|
$
|
8,601,000
|
|||
|
Net Income (Loss) Per Share
|
||||||||
|
Basic
|
$
|
(0.01
|
)
|
$
|
0.36
|
|||
|
Diluted
|
$
|
(0.01
|
)
|
$
|
0.34
|
|||
|
Weighted average common shares outstanding:
|
||||||||
|
Basic
|
23,745,848
|
23,807,014
|
||||||
|
Diluted
|
23,745,848
|
25,611,497
|
||||||
|
Cash dividends declared per share
|
$
|
0.05
|
$
|
0.05
|
||||
|
NET INCOME (LOSS)
|
$
|
(240,000
|
)
|
$
|
8,601,000
|
|||
|
OTHER COMPREHENSIVE INCOME (LOSS)
|
||||||||
|
Net unrealized holding gain (loss) on corporate bonds and notes arising during the period, net of tax
|
110,000
|
(25,000
|
)
|
|||||
|
COMPREHENSIVE INCOME (LOSS)
|
$
|
(130,000
|
)
|
$
|
8,576,000
|
|||
|
Common Stock
|
Additional
Paid-in Capital
|
Accumulated Deficit
|
Accumulated
Other Comprehensive Income (Loss)
|
Total Stockholders' Equity
|
||||||||||||||||||||
|
Shares
|
Amount
|
|||||||||||||||||||||||
|
Balance – December 31, 2018
|
23,735,927
|
$
|
237,000
|
$
|
65,151,000
|
$
|
(7,102,000
|
)
|
$
|
(81,000
|
)
|
$
|
58,205,000
|
|||||||||||
|
Dividends and dividend equivalents declared
|
—
|
—
|
—
|
(1,215,000
|
)
|
—
|
(1,215,000
|
)
|
||||||||||||||||
|
Stock-based compensation
|
—
|
—
|
144,000
|
—
|
—
|
144,000
|
||||||||||||||||||
|
Vesting of restricted stock units
|
11,250
|
—
|
—
|
—
|
—
|
—
|
||||||||||||||||||
|
Cashless exercise of options
|
35,884
|
1,000
|
(1,000
|
)
|
—
|
—
|
—
|
|||||||||||||||||
|
Treasury stock purchased and retired
|
(300
|
)
|
—
|
—
|
(1,000
|
)
|
—
|
(1,000
|
)
|
|||||||||||||||
|
Net unrealized gain on corporate bonds and notes
|
—
|
—
|
—
|
—
|
110,000
|
110,000
|
||||||||||||||||||
|
Net loss
|
—
|
—
|
—
|
(240,000
|
)
|
—
|
(240,000
|
)
|
||||||||||||||||
|
Balance – March 31, 2019
|
23,782,761
|
$
|
238,000
|
$
|
65,294,000
|
$
|
(8,558,000
|
)
|
$
|
29,000
|
$
|
57,003,000
|
||||||||||||
|
Common Stock
|
Additional
Paid-In Capital
|
Accumulated Deficit
|
Accumulated Other Comprehensive Income (Loss)
|
Total Stockholders' Equity
|
||||||||||||||||||||
| Shares | Amount | |||||||||||||||||||||||
|
Balance – December 31, 2017
|
23,843,915
|
$
|
238,000
|
$
|
64,435,000
|
$
|
(10,219,000
|
)
|
$
|
(42,000
|
)
|
$
|
54,412,000
|
|||||||||||
|
Dividends and dividend equivalents declared
|
—
|
—
|
—
|
(1,228,000
|
)
|
—
|
(1,228,000
|
)
|
||||||||||||||||
|
Stock-based compensation
|
—
|
—
|
226,000
|
—
|
—
|
226,000
|
||||||||||||||||||
|
Vesting of restricted stock units
|
11,250
|
—
|
—
|
—
|
—
|
—
|
||||||||||||||||||
|
Cashless exercise of options
|
26,890
|
1,000
|
—
|
—
|
—
|
1,000
|
||||||||||||||||||
|
Proceeds from exercise of options
|
25,000
|
1,000
|
29,000
|
—
|
—
|
30,000
|
||||||||||||||||||
|
Treasury stock purchased and retired
|
(153,993
|
)
|
(2,000
|
)
|
—
|
(397,000
|
)
|
—
|
(399,000
|
)
|
||||||||||||||
|
Net unrealized (loss) on corporate bonds and notes
|
—
|
—
|
—
|
—
|
(25,000
|
)
|
(25,000
|
)
|
||||||||||||||||
|
Net income
|
— | — | — | 8,601,000 | — | 8,601,000 | ||||||||||||||||||
|
Balance – March 31, 2018
|
23,753,062 | $ | 238,000 | $ | 64,690,000 | $ | (3,243,000 | ) | $ | (67,000 | ) | $ | 61,618,000 | |||||||||||
|
Three Months Ended
|
||||||||
|
March 31,
|
||||||||
| 2019 | 2018 | |||||||
|
CASH FLOWS FROM OPERATING ACTIVITIES:
|
||||||||
|
Net income (loss)
|
$
|
(240,000
|
)
|
$
|
8,601,000
|
|||
|
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
|
||||||||
|
Amortization of patents
|
54,000
|
70,000
|
||||||
|
Stock-based compensation
|
144,000
|
226,000
|
||||||
|
Loss from equity investment
|
96,000
|
—
|
||||||
|
Unrealized gains on marketable securities
|
(14,000
|
) |
—
|
|||||
|
Deferred tax benefit
|
(65,000
|
)
|
—
|
|||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Royalty receivables
|
(330,000
|
)
|
151,000
|
|||||
|
Prepaid taxes
|
—
|
125,000
|
||||||
|
Other current assets
|
29,000
|
22,000
|
||||||
|
Operating lease right-of-use assets
|
33,000
|
—
|
||||||
|
Accounts payable
|
328,000
|
185,000
|
||||||
|
Income taxes payable
|
—
|
2,319,000
|
||||||
|
Operating lease obligations
|
(31,000
|
)
|
—
|
|||||
|
Accrued expenses
|
(1,419,000
|
)
|
5,223,000
|
|||||
|
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES
|
(1,415,000
|
)
|
16,922,000
|
|||||
|
CASH FLOWS FROM INVESTING ACTIVITIES:
|
||||||||
|
Sales of marketable securities
|
10,586,000
|
—
|
||||||
|
Purchases of marketable securities
|
(10,068,000
|
) |
(9,761,000
|
) | ||||
|
Development of patents
|
(24,000 | ) | (27,000 | ) | ||||
|
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES
|
494,000
|
(9,788,000
|
)
|
|||||
|
CASH FLOWS FROM FINANCING ACTIVITIES:
|
||||||||
|
Cash dividends paid
|
(1,191,000
|
) |
(1,188,000
|
) | ||||
|
Repurchases of common stock, inclusive of commissions
|
(1,000
|
) |
(399,000
|
) | ||||
|
Proceeds from exercise of options and warrants
|
—
|
30,000 | ||||||
|
NET CASH USED IN FINANCING ACTIVITIES
|
(1,192,000
|
)
|
(1,557,000
|
)
|
||||
|
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
|
(2,113,000
|
)
|
5,557,000
|
|||||
|
CASH AND CASH EQUIVALENTS
, beginning of period
|
23,763,000
|
51,101,000
|
||||||
|
CASH AND CASH EQUIVALENTS
, end of period
|
$
|
21,650,000
|
$
|
56,678,000
|
||||
|
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
|
||||||||
|
Cash paid during the period for:
|
||||||||
|
Interest
|
$
|
—
|
$
|
—
|
||||
|
Income taxes
|
$
|
—
|
$
|
—
|
||||
|
NON-CASH FINANCING ACTIVITY
|
||||||||
|
Accrued dividend rights on restricted stock units
|
$
|
27,000
|
$
|
41,000
|
||||
|
[1]
|
Use of Estimates and Assumptions
|
|
[2]
|
Cash and Cash Equivalents
|
|
[3]
|
Marketable Securities
|
|
[4]
|
Revenue Recognition
|
|
·
|
identification of the license agreement;
|
|
·
|
identification of the performance obligations in the license agreement;
|
|
·
|
determination of the consideration for the license;
|
|
·
|
allocation of the transaction price to the performance obligations in the contract; and
|
|
·
|
recognition of revenue when the Company satisfies its performance obligations.
|
|
Three Months Ended March 31
|
||||||||
|
2019
|
2018
|
|||||||
|
Fully-Paid Licenses
|
$
|
130,000
|
(1) |
$
|
12,700,000
|
|||
|
Royalty Bearing Licenses
|
476,000
|
443,000
|
||||||
|
Other Revenue
|
—
|
6,320,000
|
(2) | |||||
|
Total Revenue
|
$
|
606,000
|
$
|
19
,463,000
|
||||
|
[5]
|
Equity Investments
|
|
[6]
|
Patents
|
|
[7]
|
Costs of Revenue
|
|
[8]
|
Income Taxes
|
|
[9]
|
Stock-Based Compensation
|
|
[10]
|
Earnings Per Share
|
|
[11]
|
Fair Value Measurements
|
|
[12]
|
Carrying Value, Recoverability and Impairment of Long-Lived Assets
|
|
[13]
|
Dividend Policy
|
|
[14]
|
Reclassification
|
|
[15]
|
New Accounting Standards
|
|
March 31,
2019
|
December 31,
2018
|
|||||||
|
Gross carrying amount – patents
|
$
|
7,705,000
|
$
|
7,682,000
|
||||
|
Accumulated amortization – patents
|
(5,746,000
|
) |
(5,693,000
|
)
|
||||
|
Patents, net
|
$
|
1,959,000
|
$
|
1,989,000
|
||||
|
Twelve Months Ended March 31,
|
||||
| 2020 |
$
|
280,000
|
||
| 2021 |
280,000
|
|||
| 2022 |
280,000
|
|||
| 2023 |
280,000
|
|||
| 2024 and thereafter |
839,000
|
|||
|
Total
|
$
|
1,959,000
|
|
Number of Shares
|
Weighted-Average
Grant Date Fair Value
|
|||||||
|
Balance of restricted stock units outstanding at December 31, 2018
|
505,000
|
$
|
2.17
|
|||||
|
Grants of restricted stock units
|
45,000
|
2.60
|
||||||
|
Vested restricted stock units
|
(11,250
|
)
|
2.60
|
|||||
|
Balance of unvested restricted stock units at March 31, 2019
|
538,750
|
$
|
2.20
|
|||||
|
Weighted
|
||||||||
|
Weighted
|
Average
|
|||||||
|
Range of
|
Average
|
Remaining
|
||||||
|
Exercise
|
Options
|
Exercise
|
Life in
|
Options
|
||||
|
Price
|
Outstanding
|
Price
|
Years
|
Exercisable
|
||||
|
$0.83 - $2.34
|
1,530,000
|
$1.15
|
1.33
|
1,530,000
|
|
Three Months Ended
March 31,
|
||||||||
|
2019
|
2018
|
|||||||
|
Weighted-average common shares outstanding – basic
|
23,745,848
|
23,807,014
|
||||||
|
Dilutive effect of options, warrants and restricted stock units
|
—
|
1,804,483
|
||||||
|
Weighted-average common shares outstanding – diluted
|
23,745,848
|
25,611,497
|
||||||
|
Options and restricted stock units excluded from the computation of diluted income per share because the effect of inclusion would have been anti-dilutive
|
2,068,750
|
—
|
||||||
|
March 31, 2019
|
||||||||||||||||
|
Cost
Basis
|
Gross Unrealized Gains
|
Gross Unrealized Losses
|
Fair Value
|
|||||||||||||
|
Certificates of deposit
|
$
|
11,126,000
|
$
|
—
|
$
|
—
|
$
|
11,126,000
|
||||||||
|
Short term bond funds
|
11,379,000
|
14,000
|
—
|
11,393,000
|
||||||||||||
|
Corporate bonds and notes
|
8,289,000
|
86,000
|
(57,000
|
)
|
8,318,000
|
|||||||||||
|
Total marketable securities
|
$
|
30,794,000
|
$
|
100,000
|
$
|
(57,000
|
)
|
$
|
30,837,000
|
|||||||
|
December 31, 2018
|
||||||||||||||||
|
Cost
Basis
|
Gross Unrealized Gains
|
Gross Unrealized Losses
|
Fair Value
|
|||||||||||||
|
Certificates of deposit
|
$
|
13,151,000
|
$
|
—
|
$
|
—
|
$
|
13,151,000
|
||||||||
|
Short term bond funds
|
9,648,000
|
—
|
(8,000
|
)
|
9,640,000
|
|||||||||||
|
Corporate bonds and notes
|
8,518,000
|
—
|
(81,000
|
)
|
8,437,000
|
|||||||||||
|
Total marketable securities
|
$
|
31,317,000
|
—
|
$
|
(89,000
|
)
|
$
|
31,228,000
|
||||||||
|
[1]
|
Legal Fees
|
|
[2]
|
Patent Acquisitions
|
|
[3]
|
Lease Agreements
|
|
Three Months Ended
March 31, 2019
|
||||
|
Operating lease expense
|
$
|
34,000
|
||
|
Cash paid for amounts included in the measurement of operating lease obligations
|
34,000
|
|||
|
ROU assets obtained in exchange for operating lease obligations
|
128,000
|
|||
|
As of
|
||||
|
March 31, 2019
|
||||
|
Operating lease right-of-use assets
|
$
|
95,000
|
||
|
Operating lease obligations – current
|
$
|
88,000
|
||
|
Operating lease obligations – non-current
|
8,000
|
|||
|
Total lease obligations
|
$
|
96,000
|
||
|
Weighted average remaining lease term (in months)
|
10
|
|||
|
Weighted average discount rate
|
5.5
|
%
|
||
|
Operating Leases
|
||||
|
2019 – remaining period
|
$
|
79,000
|
||
|
2020
|
20,000
|
|||
|
Total future minimum lease payments
|
99,000
|
|||
|
Less imputed interest
|
(3,000
|
)
|
||
|
Total operating lease liability
|
$
|
96,000
|
||
|
Period
|
Total
Number of
Shares
Purchased
|
Average Price
Paid Per
Share
|
Total Number of
Shares
Purchased as
Part of Publicly
Announced Plans
or Programs
|
Maximum Number
(or Approximate
Dollar Value) of
Shares that May
Yet Be Purchased
Under the Plans
or Programs
|
|
January 1 to January 31, 2019
|
300
|
2.25
|
—
|
$1,321,091
|
|
February 1 to February 28, 2019
|
—
|
—
|
—
|
$1,321,091
|
|
March 1 to March 31, 2019
|
—
|
—
|
—
|
$1,321,091
|
|
Total
|
300
|
2.25
|
—
|
| 101 |
Interactive data files:**
|
| 101.INS |
XBRL Instance Document
|
| 101.SCH |
XBRL Scheme Document
|
| 101.CAL |
XBRL Calculation Linkbase Document
|
| 101.DEF |
XBRL Definition Linkbase Document
|
| 101.LAB |
XBRL Label Linkbase Document
|
| 101.PRE |
XBRL Presentation Linkbase Document
|
|
NETWORK-1 TECHNOLOGIES, INC.
|
|||
|
Date: May 15, 2019
|
By:
|
/s/ Corey M. Horowitz | |
|
Corey M. Horowitz
|
|||
|
Chairman and Chief Executive Officer
|
|||
|
Date: May 15, 2019
|
By:
|
/s/ David C. Kahn | |
|
David C. Kahn
|
|||
|
Chief Financial Officer
|
|||
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|